You are here

  • Home
  • Archive
  • Volume 99, Issue 8
  • High uptake of vaccination against mpox in men who have sex with men (MSM) on HIV pre-exposure prophylaxis (PrEP) in Paris, France

Article Text

Article menu
Download PDFPDF
PostScript
Letter
High uptake of vaccination against mpox in men who have sex with men (MSM) on HIV pre-exposure prophylaxis (PrEP) in Paris, France
  1. Romain Palich1,
  2. Thibaut Jedrzejewski2,
  3. Luminita Schneider1,
  4. Naoual Qatib1,
  5. Thibault Orriere1,
  6. Daniel Gosset2,
  7. Thomas Grunemwald2,
  8. Dominique Pataut2,
  9. Michel Ohayon2,
  10. Christine Katlama1
  1. 1 Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France
  2. 2 Le 190 Sexual Health Center, Paris, France
  1. Correspondence to Dr Romain Palich, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Paris, France; romain.palich{at}aphp.fr

https://doi.org/10.1136/sextrans-2023-055885

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In July 2022, the French health authorities recommended smallpox vaccination (IMVANEX and JYNNEOS) to prevent mpox in population at high risk of exposure. HIV and pre-exposure prophylaxis (PrEP) physicians were informed and involved in the deployment of this vaccination, but there has been no communication to the general public. The current mpox epidemic in France, the rest of Europe and the USA is concentrated among men who have sex with men (MSM), particularly in case of multiple physical and sexual contacts.1 2 Several case series have reported high proportions of people living with HIV and of users of HIV–PrEP.3 4

    To assess the uptake of vaccination among PrEP users, we conducted an observational study in two centres in Paris, France (Infectious Diseases department of the Pitié-Salpêtrière hospital and ‘Le 190’ sexual health clinic). We systematically asked PrEP users who attended a routine check-up for PrEP at both centres between November 2022 and January 2023 whether they had received at least one vaccine dose …

    View Full Text

    Footnotes

    • Handling editor Anna Maria Geretti

    • Contributors RP, LS, MO and CK conceived and planned the experiments. RP, TJ, LS, NQ, TO, DG, TG, DP, MO and CK carried out the experiments. RP, LS, DG, MO and CK contributed to the interpretation of the results. RP took the lead in writing the manuscript. All authors provided critical feedback and helped shape the research, analysis and manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.